AX-2026-041445

Thymosin α1 · 10 mg declared · ChinaPeptides Co., Ltd. (QYAOBIO) · lot QYB-2511-V5408

PASSIDENTITY CONSISTENT

Report ID: AX-2026-041445
Compound: Thymosin α1
Compound class: Tissue-repair and immunomodulatory peptides
Supplier: QYB — ChinaPeptides Co., Ltd. (QYAOBIO)
Batch / lot: QYB-2511-V5408
Declared label claim: 10mg
Laboratory: VendorInvestigate
Assay date: 20 Feb 2026
Submitted: 21 Feb 2026
Quarter: 2026-Q1
Submitter: ro.okwuosa
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 32 min gradient, 214 nm	99.93	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — des-acetyl Tα1 (−42 Da)	0.04	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	3106.5493	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	3106.5564	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.3	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	2.73	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.16	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.17	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.57	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 32 min gradient	13.41	min	13.50 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.86	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	39,830	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated Asn (+1 Da)	1.32	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 32 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 39,830, and skew follows the reported asymmetry factor of 0.86. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.04 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Thymosin α1 — main peak	13.41	4,856,908	99.93	—
2	des-acetyl Tα1 (−42 Da)	12.68	1,944	0.04	-42.011
3	deamidated Asn (+1 Da)	13.05	1,458	0.03	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 3106.5493 Da, computed from C129H215N33O55. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 3106.5564 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
5+	622.3171	622.3186	0.0015	8.1
4+	777.6446	777.6464	0.0018	55.8
3+	1036.5237	1036.5261	0.0024	100.0
2+	1554.2819	1554.2855	0.0036	55.3

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.93	divergence +0.14 pp vs batch median
Total impurities (% area)	not stated	0.07
Largest single impurity (% area)	not stated	0.04
Water (%)	0.5	2.73
Counter-ion (%)	5.6	5.16
Peptide content (%w/w)	93.3	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Domestic warehouse despatch → submitter (2–8 °C, 1 d) → laboratory (courier, cold pack, 2 d) → assay.
Assay date: 20 Feb 2026
Submitted to the index: 21 Feb 2026
Laboratory: VendorInvestigate, Riga, Latvia
Method basis: 32 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

scale_up_delta21 Feb 2026

Purity usually falls between gram and kilogram scale. A figure of 99.93 % on a commercial lot rather than a laboratory batch is the more informative version of this result.

esi_tof21 Feb 2026

The observed monoisotopic mass on this record reconciles with the theoretical value to four decimal places, which is the arithmetic the index re-derives in its own build check rather than accepting from the report.

Section 7

Related records

Same batch — lot QYB-2511-V5408 n=12

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041437	QYB-2511-V5408	PeptideMeter	2026-Q1	99.75	2.57	92.0	Buyer-sourced	0	PASS
AX-2026-041438	QYB-2511-V5408	Janoshik	2026-Q1	99.80	2.70	105.2	Buyer-sourced	0	PASS
AX-2026-041439	QYB-2511-V5408	PeptideMeter	2026-Q1	99.51	2.59	105.3	Buyer-sourced	0	PASS
AX-2026-041440	QYB-2511-V5408	VendorInvestigate	2026-Q1	99.81	3.10	101.9	Buyer-sourced	0	PASS
AX-2026-041441	QYB-2511-V5408	Janoshik	2026-Q1	99.68	2.72	—	Buyer-sourced	0	PASS
AX-2026-041442	QYB-2511-V5408	Kestrel	2026-Q1	99.82	2.35	96.1	Buyer-sourced	0	PASS
AX-2026-041443	QYB-2511-V5408	VendorInvestigate	2026-Q1	99.54	2.88	—	Buyer-sourced	0	PASS
AX-2026-041444	QYB-2511-V5408	PeptideMeter	2026-Q1	99.58	2.93	—	Buyer-sourced	0	PASS
AX-2026-041446	QYB-2511-V5408	PeptideMeter	2026-Q1	99.40	2.66	98.9	Buyer-sourced	0	PASS
AX-2026-041447	QYB-2511-V5408	Janoshik	2026-Q1	99.93	2.34	—	Buyer-sourced	0	PASS
AX-2026-041448	QYB-2511-V5408	Janoshik	2026-Q1	99.77	2.54	89.9	Laboratory-retained	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Thymosin α1 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041996	AMB	AMB-2511-B5683	VendorInvestigate	2026-Q2	99.31	4.20	91.2	Buyer-sourced	0	PASS
AX-2026-041995	AMB	AMB-2511-B5683	PeptideMeter	2026-Q2	98.86	4.00	104.5	Buyer-sourced	0	PASS
AX-2026-041998	AMB	AMB-2511-B5683	Nordanalyt	2026-Q2	99.08	3.83	—	Buyer-sourced	0	PASS
AX-2026-043232	SGN	SGN-2512-Y9621	Janoshik	2026-Q2	99.42	6.88	89.1	Buyer-sourced	1	MARGINAL
AX-2026-041999	AMB	AMB-2511-B5683	Medutest	2026-Q2	99.93	3.95	102.2	Supplier-supplied	1	MARGINAL
AX-2026-041997	AMB	AMB-2511-B5683	PeptideMeter	2026-Q2	99.11	4.26	104.3	Buyer-sourced	0	PASS
AX-2026-041442	QYB	QYB-2511-V5408	Kestrel	2026-Q1	99.82	2.35	96.1	Buyer-sourced	0	PASS
AX-2026-041438	QYB	QYB-2511-V5408	Janoshik	2026-Q1	99.80	2.70	105.2	Buyer-sourced	0	PASS

Other recent QYB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041471	PT-141 (Bremelanotide)	QYB-2607-L4875	Janoshik	2026-Q3	99.72	3.75	101.7	Buyer-sourced	0	PASS
AX-2026-041377	Ipamorelin	QYB-2605-H3558	Nordanalyt	2026-Q3	99.93	4.35	—	Buyer-sourced	0	PASS
AX-2026-041427	Retatrutide	QYB-2604-B4920	PeptideMeter	2026-Q3	97.93	2.45	101.7	Buyer-sourced	0	PASS
AX-2026-041428	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.35	3.20	—	Laboratory-retained	0	PASS
AX-2026-041473	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.58	3.74	94.4	Buyer-sourced	0	PASS
AX-2026-041472	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041429	Retatrutide	QYB-2604-B4920	Medutest	2026-Q3	98.53	2.69	99.8	Buyer-sourced	1	MARGINAL
AX-2026-041431	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.63	2.32	94.2	Buyer-sourced	0	PASS